Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomised, within-participants cross-over design trial including 34 patients with systemic lupus erythematosus. The participants will be randomised to data registration of patient reported outcome measures (PROM) through the DANBIO webapp and thereafter via the outpatient touchscreen or vice versa.
The aim of this trial is to evaluate whether electronic reporting of PROMs through the DANBIO web application (webapp) is comparable to the outpatient touchscreen among patients with SLE.
The trial is a randomised, crossover, agreement study where 34 patients with SLE from the Department of Rheumatology at Aalborg University Hospital will be included and randomised in ratio 1:1 to:
There will be a wash-out period of 1-2 day between the two registrations to minimise carryover bias.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group WT | Other | PROM registration via the DANBIO WebApp and thereafter the outpatient touchscreen |
|
| Group TW | Other | PROM registration via the outpatient touchscreen and thereafter the DANBIO WebApp |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order | Device | PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Systemic Lupus Activity Questionnaire global health | Evaluates global assessment of lupus activity using an NRS score from 0-10. Higher score Means worse outcome. | Day 1 (first data registration) and day 3 (second data registration) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Health Assessment Questionnaire (HAQ) | Assess the patient's physical function from 0-3. Higher score Means worse outcome. | Day 1 (first data registration) and day 3 (second data registration) |
| Visual Analogue Scale for Pain |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Salome Kristensen, MD, PhD | Department of Rheumatology, Aalborg University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Rheumatology | Aalborg | 9000 | Denmark |
Study protocol and the SAP will be published as supplementary information to the article. IPD from this trial that underlie results in a publication will be made available in clinicaltrials.gov after publication of the article.
Will be made available when the article is published
Study protocol and the SAP will be published as supplementary information to the article. IPD from this trial that underlie results in a publication will be made available in clinicaltrials.gov after publication of the article.
Not provided
Not provided
| ID | Term |
|---|---|
| D008180 | Lupus Erythematosus, Systemic |
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
A randomised, within-participants, open, cross-over trial
Not provided
Not provided
Not provided
Not provided
The patient's assessment of pain on a scale from 0-100 within the last week.The left of the scale (0) signifies the absence of pain and the right end (100) maximum pain.
| Day 1 (first data registration) and day 3 (second data registration) |
| Visual Analogue Scale for fatigue | The patient's assessment of fatigue on a scale from 0-100 within the last week. The left of the scale (0) signifies the absence of fatigue and the right end (100) maximum fatigue. | Day 1 (first data registration) and day 3 (second data registration) |
| Patient Global Visual Analogue Scale | The patient's global assessment of disease activity (arthritis severity) on a scale from 0-100 within the last week. The left of the scale (0) signifies the absence of arthritis activity and the right end (100) maximum arthritis activity. | Day 1 (first data registration) and day 3 (second data registration) |
| Patient Acceptable Symptom State (PASS) | The patient's assessment of acceptable symptom state. Consist of one question answered with "yes" or "no". The question is: ''Take into account all the ways in which your arthritis has affected you in the past 48 hours. If you were to remain for the next few months as you are today, would it be acceptable to you?" | Day 1 (first data registration) and day 3 (second data registration) |
| Anchoring question | The patient's assessment of change in arthritis activity since last visit from much worse to much better. | Day 1 (first data registration) and day 3 (second data registration) |
| SLAQ flare score | Evaluates presence or severity of lupus flare on a transitional scale e.g. 0 (no worsening), 1 (mild worsening), 2 (moderate worsening) or 3 (severe worsening). | Day 1 (first data registration) and day 3 (second data registration) |
| SLAQ symptom score | Evaluates the number of lupus specific symptoms present from 0-24. Higher score means worse outcome. | Day 1 (first data registration) and day 3 (second data registration) |
| SLAQ total score | Evaluates severity of lupus disease activity by a weighted score of the 24 lupus specific symptoms, range 0-44. Higher score means worse outcome. | Day 1 (first data registration) and day 3 (second data registration) |